55 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
were expensed as research and development (R&D) expense. This resulted in inventory being sold during the 2022 and 2023 periods, for which a portion … ,
Revenue:
Product revenue, net
Licensing and other revenue
Total revenue:
Operating expenses:
Cost of sales
Research and development
General
CORRESP
APLS
Apellis Pharmaceuticals Inc
20 Nov 23
Correspondence with SEC
12:00am
Financial Operations Overview
Research and Development Expenses, page 33
You disclose that you have not provided program costs since inception … because historically you have not tracked or recorded your research and development expenses on a program-by-program basis. Please tell us whether you
UPLOAD
1bus2xafo8lv
8 Nov 23
Letter from SEC
12:00am
424B5
a2kxcz8q0 o2xq20rt
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
EX-99.1
la6z 98n4
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
424B5
3yljlg
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
k2qxragu9a3t
23 Mar 22
Prospectus supplement for primary offering
5:14pm
424B5
z12qbq19
20 Jan 22
Prospectus supplement for primary offering
4:45pm